Skip to main content
Article thumbnail
Location of Repository

Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis

By Joan S Lewis-Wambi, Helen R Kim, Chris Wambi, Roshani Patel, Jennifer R Pyle, Andres J Klein-Szanto and V Craig Jordan
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1980). A simple, rapid, and sensitive DNA assay procedure. Anal Biochem
    2. (2001). A: High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat
    3. (1989). A: Mitochondrial damage in muscle occurs after marked depletion of glutathione and is prevented by giving glutathione monoester.
    4. (1985). A: Origin and turnover of mitochondrial glutathione.
    5. (2008). A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol
    6. (2007). Allred DC: The estrogen paradox. Nat Clin Pract Endocrinol Metab
    7. (1999). BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic Biol Med
    8. (2008). Blackwell KL: Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. Clin Breast Cancer
    9. (2006). Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. Cancer Res
    10. (1997). Chem
    11. (1993). DE: Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science
    12. (2006). Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene
    13. (2006). Debatin KM: Targeting inhibitor of apoptosis proteins (IAPs) for diagnosis and treatment of human diseases. Recent Patents Anticancer Drug Discov
    14. (1944). E: Influence of synthetic oestrogens upon advanced malignant disease. BMJ
    15. (2008). Eguchi H: Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol
    16. EJ: Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic action of Bcl-
    17. (2003). Ferguson-Miller S: Mitochondria: releasing power for life and unleashing the machineries of death. Cell
    18. (1998). Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact
    19. (1997). Induction of apoptosis by the transcription factor c-Jun.
    20. (2003). KJ: Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res
    21. (2005). Kregel KC: Aging reduces responsiveness to BSO- and heat stressinduced perturbations of glutathione and antioxidant enzymes.
    22. (1998). ML: Expression of Bcl-2 increases intracellular glutathione by inhibiting methionine-dependent GSH efflux. Biochem Biophys Res Commun
    23. (2001). Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes.
    24. (2000). Nussler AK: Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer
    25. (2003). O'Dwyer PJ: Role of Jun and Jun kinase in resistance of cancer cells to therapy. Drug Resist Updat
    26. (2007). O'Malley BW: Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
    27. (1996). Ozols RF: Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    28. (1995). Programmed cell death and Bcl-2 protection in very low oxygen. Nature
    29. (1997). Resistance to radiation-induced apoptosis in Bcl2-expressing cells is reversed by depleting cellular thiols. Oncogene
    30. (1999). Reynolds CP: Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res
    31. (1996). RF: Glutathione and drug resistance. Cancer Invest
    32. (2001). Santen RJ: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol.
    33. (1986). Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res
    34. (1996). Shift of the cellular oxidation-reduction potential in neural cells expressing Bcl-2.
    35. (1989). Sinha BK: Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res
    36. (1994). Spriggs DR: Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    37. (2003). Tapiero H: The importance of glutathione in human disease. Biomed Pharmacother
    38. (2008). The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer – survival or death? J Clin Oncol
    39. (1995). Thiol-mediated redox regulation of apoptosis. Possible roles of cellular thiols other than glutathione in T cell apoptosis.
    40. (1997). Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res
    41. (1996). Uthus EO: Suppression of plasma estradiol and progesterone concentrations by buthionine sulfoximine in female rats. Biochem Pharmacol
    42. (1995). VC: An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res
    43. (1998). VC: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
    44. (2005). VC: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.
    45. (2008). VC: Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer
    46. (1987). Vistica DT: Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Cancer Res
    47. (1997). Wilding G: Phase I study of continuous-infusion L-S, R-buthionine sulfoximine with intravenous melphalan.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.